Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Catalyst Bio (NQ: CBIO)
8.360 USD  -0.020 (-0.24%)
Official Closing Price  /  Updated: 5:16 PM EST, Feb 22, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 101,000
Open 8.390
Bid (Size) 7.790 (1)
Ask (Size) 9.000 (10)
Prev. Close 8.380
Today's Range 8.310 - 8.640
52wk Range 6.200 - 31.52
Shares Outstanding 11,935,169
Dividend Yield N/A
Performance
YTD
+1.33%
+1.33%
1 Month
+7.87%
+7.87%
3 Month
-22.59%
-22.59%
6 Month
-24.34%
-24.34%
1 Year
-68.51%
-68.51%
Top News
More News
New Research: Key Drivers of Growth for Omega Healthcare Investors, Cinedigm, Cardiovascular, Allegiant Travel, Catalyst Biosciences, and ESCO Technologies — Factors of Influence, Major Initiatives an
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Omega Healthcare... Read More
from GlobeNewswire News Releases
Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
Catalyst Biosciences, Inc. (NASDAQ: CBIO), presented updated interim data from the Phase 2/3 trial of subcutaneous prophylactic Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA)... Read More
from GlobeNewswire News Releases
More News
Read More
Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B
from GlobeNewswire News Releases
Catalyst Biosciences to Present at the Annual BIO CEO & Investor Conference
from GlobeNewswire News Releases
Catalyst Biosciences Announces Oral and Poster Presentations at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders
from GlobeNewswire News Releases
Analysts Anticipate 10% Gains Ahead For IWN
category ETFs
from ETF Channel
Catalyst Biosciences Hosts Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs
from GlobeNewswire News Releases
Notable Friday Option Activity: X, ABUS, CBIO
category Stocks
from Market News Video
Peek Under The Hood: IWN Has 21% Upside
category ETFs
from ETF Channel
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
category KRR , Benzinga , Market News , and 12 more.
from Benzinga
5 Stocks To Watch For December 24, 2018
category Market News , Benzinga , Stocks To Watch , and 10 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.